Illumina, a San Diego-based provider of sequencing and array-based technologies, has formed a collaboration with Merck Serono, the biopharmaceuticals business of Merck, based in Darmstadt, Germany, to develop a universal next-generation sequencing (NGS)-based oncology diagnostic.
In addition to separate collaborations with AstraZeneca, Janssen Biotech and Sanofi, Illumina and Merck Serono will work to create a universal test system for clinical trials of targeted cancer therapies, with the goal of a more comprehensive tool for precision medicine.
Illumina is working with Merck Serono to develop assays that detect and measure multiple variants simultaneously to support clinical trials. The collaboration toward the universal cancer test will include test development, worldwide regulatory approvals and global commercialization. In parallel, Illumina continues to collaborate with the Actionable Genome Consortium to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm.
“Our collaboration with Illumina around next-generation sequencing will enable us to perform genome studies at a pace unheard of a few years ago, and could lead to the development of several diagnostics,” said Susan Herbert, head of Global Business Development at Merck Serono.
“This agreement is another step forward in realizing the promise of precision medicine,” said Richard Klausner, M.D., Illumina’s chief medical officer. “The U.S. government’s Precision Medicine Initiative, recently announced by President Obama, specifically outlines the need to expand genetically-based clinical trials as a key approach for developing better treatments for cancer.”